Background: Major shoulder surgery is associated with moderate-to-severe pain, but consensus on the optimal analgesic approach is lacking. Continuous catheter-based interscalene block (CISB) prolongs the analgesic benefits of its singleinjection counterpart (SISB), but concerns over CISB complications and difficulties in interpreting comparative evidence examining major and minor shoulder procedures simultaneously, despite their differences in postoperative pain, have limited CISB popularity. This meta-analysis evaluates the CISB analgesic role and complications compared with SISB for major shoulder surgery. Methods: We retrieved randomised controlled trials (RCTs) comparing the effects of CISB to SISB on analgesic outcomes and side-effects after major shoulder surgery. Postoperative opioid consumption at 24 h was designated as the primary outcome. Secondary outcomes included 24e48 h opioid consumption, postoperative rest and dynamic pain scores up to 72 h, time-to-first analgesic, recovery room and hospital stay durations, patient satisfaction, postoperative nausea and vomiting, respiratory function, and block-related complications. Results: Data from 15 RCTs were pooled using random-effects modelling. Compared with SISB, CISB reduced 24-and 48-h oral morphine consumption by a weighted mean difference [95% confidence interval] of 50.9 mg [e81.6, e20.2], (P¼0.001) and 44.7 mg [e80.9, e8.7], (P<0.0001), respectively. Additionally, CISB provided superior rest and dynamic pain control beyond 48 h, prolonged time-to-first analgesic, enhanced satisfaction, and reduced postoperative nausea and vomiting without complications. CISB caused an 11.0e11.7% decrease in respiratory indices. Result heterogeneity was successfully explained.
Single-injection interscalene block (SISB) of the brachial plexus is a popular and easy to perform technique that provides effective pain control up to 8 h 1 after minor shoulder surgeries. 2e4 For major shoulder surgeries, after which the duration of moderate-to-severe acute pain extends into the first 48 h, continuous catheter-based interscalene block (CISB) may provide prolonged postoperative analgesia. 2,5e7 However, consensus over the ideal interscalene block modality for major shoulder surgery is lacking for several reasons. First, clear evidence for the superiority of CISB is missing. Clinical trials comparing CISB with SISB have included both major and minor procedures, despite different degrees in postoperative pain, making meaningful interpretation of the evidence difficult. Second, CISB requires additional time and technical skill for insertion, and more resources for procurement and management. 8 Of concern, potentially serious complications have been associated with the use of CISB, including catheter malposition (1.5%), 9,10 dislodgement (1.5%), 9, 11, 12 infection (3%), 13 myotoxicity (0.05%), 14 phrenic nerve block (100%), 15, 16 and even a potential risk of compression leading to persistent hemi-diaphragmatic palsy. 12, 17 Consequently, concerns regarding the safety of CISB has limited its clinical use. 18 In fact, there have been calls dissuading anaesthetists who contemplate setting up a CISB service in their centres. 8 Given these issues, the objective of this systematic review and meta-analysis is to evaluate the analgesic benefits and side effects profile of CISB for major shoulder surgery. We hypothesise that CISB provides superior postoperative analgesia by reducing the cumulative analgesic consumption at 24 h postoperatively.
Methods
The authors followed the preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement guidelines 19 in the preparation of this manuscript. Randomised and quasi-randomised controlled trials (RCT) examining the effect of CISB on analgesia after major shoulder surgery were evaluated using a predesigned protocol.
Literature search
Two of the authors (L.V. and F.W.A.) independently sought and retrieved relevant studies from electronic databases including the US National Library of Medicine database, Medline; Medline In-Process; EMBASE; Excerpta Medica; Cochrane Central Register of Controlled Trials; Cochrane Database of Systematic Reviews; Scopus; Web of Science Core Collection; and other nonindexed databases of citations (AMED, CINAHL, BIOSIS). Medical subject headings (MeSH), controlled terms, and text words relating to interscalene block such as interscalene, nerve block, and brachial plexus were combined using the Boolean operator AND with search terms relating to shoulder surgery, including grouped or individually named anatomical terms such as rotator cuff, biceps; procedural terms such as surgical procedures, arthroscopy, arthroplasty, reconstruction, fixation, repair, stabilisation, decompression, revision, excision, plication, tenodesis, acromioplasty, Bankart; and surgical instruments such as bone nails, anchors, prosthesis, plates, screws, and wires. 
Eligibility criteria
We included RCTs with parallel group design examining the effects of CISB compared with SISB on postoperative analgesic outcomes in patients undergoing major shoulder surgery. We considered procedures as rotator cuff repair, Bankart repair, biceps tenodesis, anterior shoulder stabilisation, 21, 22 and arthroplasty as major shoulder procedures; while simple arthroscopy (þ/e debridement), subacromial decompression (þ/e acromioplasty), capsular plication, and excision lateral clavicle were considered as minor procedures. 23 Based on a preliminary literature search, we determined that trials limited to major shoulder surgery are rare, 24, 25 and most published trials did not make a distinction between minor and major shoulder surgeries. 26e33 We therefore decided to include
RCTs where the majority (more than half), if not all, of the patients examined underwent major shoulder surgery. Trials examining populations having minor shoulder surgeries and those with patients having major shoulder constituted the minority, were excluded. Blocks administered for surgical anaesthesia or postoperative analgesia were considered. RCTs comparing different bolus or infusion regimens of CISB, 34e36 or CISB with other analgesic strategies (e.g. local infiltration, 37 continuous intra-articular, subacromial, or cervical epidural infusions 38 ) in the absence of an SISB group were excluded. Also excluded were studies that examined multiple types of continuous peripheral nerve blocks simultaneously, 39 where the effects of CISB could not be assessed in isolation from other blocks. RCTs that did not report any analgesic outcomes (i.e. pain severity, duration of analgesia, opioid consumption, discharge times, or opioid-related side effects) were also excluded. Studies limited to 10 or fewer patients were not included to minimise the probability of detecting a treatment effect by mere chance.
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Trial selection and methodological assessment
Identified abstracts were independently evaluated by two authors (L.V. and F.W.A.). Inclusion of qualifying studies was subject to consensus between the two authors. Disagreements were resolved by re-evaluating the full manuscript of the source studies and consulting with a third author (R.B.).
RCTs that failed to meet the inclusion criteria were excluded. The quality of the reviewed RCTs was independently assessed by two of the authors (L.V. and F.W.A.) using the Cochrane Collaboration Risk of Bias tool. 42 The tool evaluates
RCTs for several types of bias, among which are selection (randomisation and allocation), performance and detection (blinding), attrition, reporting, and other forms of bias. Grading was assigned to each RCT by consensus; if an agreement could not be reached, the third author (R.B.) was consulted. We did not exclude any trials based on the risk of bias, but we planned to examine the effect of any trials assigned an overall high risk of bias using subgroup analysis.
Data extraction
The authors independently extracted relevant data using a standardised data sheet; discrepancies were resolved by reexamining the source data as a first resort, then consulting with the third author (R.B.). Data extracted included primary author, year of publication, comparative groups, sample size, number of patients per study group, patient disposition, surgical procedure, surgical anaesthesia modality, ISB localisation technique (landmark, nerve stimulation, or ultrasound), ISB bolus and continuous infusion local anaesthetic type and dose, duration of CISB, primary and secondary outcomes and their definitions, and pre-, intra-, and postoperative analgesic adjuncts.
Outcomes assessed
We designated cumulative analgesic consumption in the first 24 h postoperative period, expressed as oral morphine equivalents (mg) 43 as a primary outcome. Secondary outcomes included cumulative 24e48-and 48e72-h analgesic consumption, resting and dynamic pain severity visual analogue scale (VAS; 0¼no pain, 10¼worst pain imaginable) scores at postoperative time intervals ranging from 0 to 72 h, patient satisfaction (VAS), time to first analgesic request, postanaesthesia care unit (PACU) stay (h), hospital discharge time (h), risk of postoperative nausea and vomiting (PONV), motor block, respiratory function, and block-related complications. The CISB-related technical difficulties examined included the incidence of catheter malposition and dislodgement.
For the purpose of this review, we converted verbal rating scale scores and pain numerical rating scale scores to VAS. 44 We also converted all postoperative opioid analgesics to equi-analgesic doses of oral morphine. 43 Dichotomous outcome results describing the occurrence of opioid consumption during a specified time interval 45 were converted to frequencies (n/N). The single lowest frequency (at least once) was used to estimate the proportion of patients requiring opioid supplementation and the dose used. We assessed patient satisfaction with postoperative analgesia using a VAS score (10 ¼ most satisfied, 0 ¼ least satisfied).
Predefined sources of heterogeneity
To explore potential causes of heterogeneity in our results, we pre-identified the clinical characteristics of individual RCTs that may lead to variations in our primary outcome results. The variables of interest included: i) disposition (ambulatory vs inpatient); ii) anaesthetic technique (general vs regional anaesthesia); iii) block localisation technique; iv) SISB local anaesthetic (LA) activity (short-vs long-acting); v) CISB LA loading dose; vi) duration of infusion for CISB; vii) method of CISB LA delivery (basal infusion, bolus, or both); viii) surgical procedure performed (major shoulder surgery alone vs major and minor shoulder surgery); ix) surgical approach (open vs arthroscopic); x) use of multimodal analgesia; xi) randomisation technique (randomised vs quasirandomised); and xii) overall risk of bias. The degree to which these additional factors predict the 24-h analgesic consumption (primary outcome) was evaluated using metaregression analysis. Furthermore, to examine whether the eligibility criteria has influenced the direction or magnitude of the treatment effect, we planned a sensitivity analysis to examine the effect of including trials with a minority of patients having minor shoulder surgeries. Moreover, we planned an additional subgroup analysis to examine the effect of the type of major shoulder surgery on the primary outcome examined.
Statistical analysis
Data presented in tables or in text were used as the primary source for extraction; when data were not reported, we attempted to contact authors for the raw data. If raw data could not be obtained, graphical data not otherwise available in text were estimated from figures using a graph digitising software (GraphClick, Arizona Software, Neuchatel, Switzerland). Lastly, when standard deviation (SD) values were not reported for an outcome, they were imputed based on data within one of the two subgroups. 46, 47 Dichotomous data relating to side-effects were converted to incidence (n/N) during a given time interval, and the single-highest incidence was used to capture the proportion of patients who experienced a certain side-effect at least once.
Where reported, the range and inter-quartile range were used to estimate the SD, using the formulas SD¼range/4 and SD¼inter-quartile range/1.35, respectively, as described by the Cochrane Handbook for Systematic Reviews. 48 Data reported as 95% confidence intervals (CI) were also used to estimate the range and converted to SD. The median was used to estimate the mean if the value was not reported. 49 Data from trials with more than two intervention groups receiving different doses of LA 50 or different CISB techniques 51 were combined into a single group as per the Cochrane Handbook. 47 We analysed results on an intention-to-treat basis by analysing the data available from all participants in each study group, regardless of compliance or attrition, to estimate the influence on treatment effect. 53 were used to combine the data where possible. The random-effects modelling was selected for pooling data. We decided pre-hoc to consider pooling data to be feasible only if data from at least three RCTs were available. The odds ratio (OR) and 95% CI were reported for dichotomous outcomes, while the weighted mean difference (WMD) and 95% CI were reported for continuous outcomes. Differences were considered statistically significant when the Pvalue was <0.05 and the 95% CI did not include 1 for OR and 0 for the WMD. For time-to-event outcomes, including time to first analgesic request, duration of PACU stay, and time to hospital discharge, the ratio of means (ROM), standard error, and 95% CIs were calculated for all continuous outcomes examining change from baseline (e.g. time to first analgesic request, PACU stay, hospital discharge time). 54, 55 We assessed the strength of pooled evidence using Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) guidelines. 56, 57 Based on study quality, consistency, directness, precision, and publication bias, these guidelines classify the strength of evidence into strong, moderate, low, or very low quality. Heterogeneity of the pooled results was assessed using the I 2 statistic. 34 When heterogeneity was significant (I 2 >50%), we planned to explore the sources of heterogeneity of the primary outcome data by examining the association with the prespecified confounders using meta-regression analysis and subgroup analysis. The risk of publication bias was evaluated by checking for asymmetry of the funnel plots, as described in the Egger regression test.
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Results
Our literature search retrieved 828 unique records, after excluding duplicates. Of these, 806 were excluded after initial screening. Two trials were further excluded on the basis of insufficient sample size, 40, 41 and another was excluded because it examined minor shoulder surgeries. 23 ; labral repair and biceps tenodesis were evaluated in one trial 61 ; and shoulder arthroplasty was examined in six trials. 5e7, 50, 51, 59 None of the trials examined arthroplasty as the only surgical procedure, while four trials assessed rotator cuff repair exclusively. 24, 25, 63, 65 Risk of bias assessment
The reviewers' consensus assessment of the risk is detailed in supplemental Fig 1. Most trials had low risk for selection bias, attrition bias, and reporting bias. The majority of trials had unclear risk of performance and detection biases because only a few used placebo injections and/or dressings, and because of the lack of sufficient details of the measures taken to maintain blinding and concealment of allocation. Only one trial was assigned a high risk of bias 50 because of its quasi-randomised nature. The overall risk of bias across the remaining studies was rated as low.
Cumulative 24-h analgesic consumption
Data describing the primary outcome, cumulative postoperative analgesic consumption during the first 24 hour postsurgery were available from seven trials 11, 25, 45, 59, 60, 64, 65 for 318
patients. The SD for this outcome was not reported and was estimated from the range or the 95% CI in three trials. 25, 45, 63 Compared with SISB, administering CISB reduced the cumulative oral morphine equivalent consumption at 24 h postoperatively by 50.9 mg [e81.6, e20.2] (P¼0.001; Fig. 2A) . Table 3 summarises the outcome results and the assigned GRADE 56 of evidence for each outcome.
The primary outcome results were characterised by significant heterogeneity. Performing meta-regression analysis using the a priori defined confounders yielded statistically significant omnibus P-values for three of the pre-defined potential sources of heterogeneity, namely the: i) type of LA used (short-vs long-acting, P<0.0001); ii) CISB LA loading dose (P¼0.001); and iii) duration of CISB infusion (P<0.0001), indicating that these three factors were predictors of the primary outcome results. The risk of publication bias in our primary outcome results, as examined by the funnel plot and Egger's test, was not significant (P¼0.09).
Sensitivity analysis by excluding trials 45, 60 with a minority of minor shoulder surgeries confirmed that the contribution of these trials to the primary outcome results was minimal. Examined in the setting of trials of major shoulder surgery per se, CISB reduced the cumulative opioid consumption at 24 h postoperatively by e48.1 mg [e83.3, e13.0] (P<0.00001). Subgroup analysis examining the effect of CISB on each specific type of major shoulder surgery suggested that CISB reduced the cumulative opioid consumption at 24 h postoperatively by e57.1 mg [e87.4, e26.8] (P¼0.0002) for patients having rotator cuff repair. All other major shoulder procedures were examined in studies where rotator cuff repair surgery was also examined, precluding a meaningful subgroup analysis. 
Secondary outcomes
24e48-h analgesic consumption
48e72-h analgesic consumption
A paucity of trials examining this outcome precluded pooling of data. Only one trial 25 compared the effect of CISB with SISB and reported a 50% reduction in oral morphine equivalent consumption (P<0.0001) for the 48e72-h interval.
Rest pain
The time at which the effect of CISB on postoperative rest pain severity scores was assessed varied among trials, including 0, was not significant at 0, 2, 6, and 8 h postoperatively. Figure 3 presents weighted mean difference for rest pain across time. 
Duration of PACU stay
The duration of PACU stay was evaluated in one trial only. 45 CISB did not affect the time to PACU discharge, with a ROM of e0.2 [e1.1, 0.7] (P¼0.7).
Time to hospital discharge
The duration of hospital stay was evaluated in one trial only. 
Postoperative nausea and vomiting
The risk of PONV was evaluated in six trials. 
Motor block
Motor block was examined in two trials 5, 6 ; however, variability in the definitions and time intervals assessed precluded pooling. Qualitatively, no statistically significant differences in motor block were observed among these trials. Specifically, the two trials by Borgeat and colleagues 5, 6 defined motor block as difficulty in finger flexion or extension at 12 h after shoulder surgery with ISB, and reported that CISB was associated with 35% risk of motor block, compared with 20% in SISB group in the first study. 5 The risk rates were not reported in the second. 6 
Respiratory function
Respiratory function was examined in two trials. 7, 50 Administering CISB resulted in a deterioration of the various spirometry parameters at 24 h postoperatively, compared with SISB. Measuring the change as a fraction of the baseline, CISB decreased the forced expiratory volume in the first second, forced vital capacity, and peak expiratory flow by e0. No differences were observed in the diaphragmatic excursion between CISB and SISB. As for respiratory complications, one of the two trials reported no hypoxaemic episodes in either study arm, 7 while the other 50 reported a 50% incidence of hypoxaemic episodes, defined as SpO 2 <90%, in the CISB group during the evening after surgery; but this incidence for the SISB group was not reported. None of the trials reported other respiratory complications, such as prolonged respiratory support or need for re-intubation.
Complications and technical difficulties
Finally, trials reporting on CISB-related technical difficulties (catheter malposition 5, 6, 25, 45, 51, 59, 61, 62 and dislodgement 5, 6, 51, 60, 62 ) noted a total of 11 dislodged catheters and five instances of failure to thread the CISB catheter to the desired anatomical position. This relatively low complication rate is notable considering the diversity of localisation techniques used, and the variety of catheter fixation techniques used, which included suturing, 50, 62 tunneling, 51, 60, 61 taping, 5e7 and anchoring.
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Discussion
Our systematic review and meta-analysis provides evidence that CISB confers important analgesic benefits after major shoulder surgery without increasing side-effects or block complications. Importantly, our results demonstrate the prolonged analgesic benefits and superiority of infusion-based CISB over the single bolus-based SISB. Compared with SISB, CISB reduced cumulative postoperative opioid consumption up to 48 h (high evidence), and decreased postoperative resting and dynamic pain scores in the 12e48-h (moderateehigh evidence) and 24e72-h (lowehigh evidence) intervals, respectively. These benefits seem to be particularly applicable to rotator cuff repair surgery. Additional benefits of CISB include improved patient satisfaction (moderate evidence) and lower incidence of PONV (high evidence). Importantly, we found no evidence for CISB-related complications or catheter-related technical issues in this systematic review. While CISB was associated with a small impairment in physiological indices of respiratory function that seemed to be well-tolerated by healthy study participants (very low evidence), 68 this may be clinically relevant in high-risk subjects. 69, 70 The effects of CISB on motor function could not be ascertained because of the variability in outcome measures in a small number of trials. These findings were marked by significant heterogeneity, but the heterogeneity was explained by the longevity, bolus dose, and duration of infusion of the local anaesthetics used in the CISB.
The clinical implications of our review provide important insights into the controversy of routine CISB use for major shoulder surgery: while both CISB and SISB were similarly effective in reducing rest pain severity up to 8 h, CISB continues to produce clinically important improvements in rest pain between 12 and 48 h, well beyond the duration of analgesia of the SISB. Additionally, CISB reduces opioid consumption by clinically important amounts (>50 mg of oral morphine equivalent) compared with SISB during the first 24 h after major shoulder surgery. These differences emphasise the limited analgesic duration of SISB 1 and prove that major shoulder surgery patients continue to experience clinically important pain levels after the wear off of SISB. The lack of difference in the time-to-first analgesic request between the two groups was noteworthy; but that can be attributed to breakthrough pain when the surgical block (initial bolus) wears off in the CISB group. 71, 72 The observed comparative efficacy of CISB, together with accumulating evidence of its benefits, 73 and recent evidence supporting its safety and practicality, 9 help in closing the evidence gap in the use of CISB in this surgical population. Indeed, the lack of clarity of benefits has contributed to the heterogeneity of practice. CISB has been reserved for shoulder arthroplasty in some centers, 2,5e7 while others offer SISB for both major and minor shoulder procedures, 18 as evident in numerous clinical trials. This is the first systematic review to support maintaining a CISB infusion for at least 48 h after major shoulder surgery to optimise pain control and overcome the limited duration of analgesia associated with SISB. 1 The decision to extend the infusion into the 3rd day after surgery seems to be beneficial, but the paucity of evidence does not support any recommendations. Nonetheless, the decision to routinely use CISB for major shoulder surgery needs to be balanced against the potential risk of respiratory complications, particularly in highrisk patients, in addition to other factors such as logistic challenges, and the potential risks of catheter placement and maintenance. However, the potential for CISB to reduce opiate requirements may also be an advantage in patients with compromised respiratory function. Before this review, CISB was supported by some good quality trials 45, 74, 75 ; but the largest body of supporting evidence has been retrospective, and thus not very compelling. 9 An earlier review that compared all types of single-injection vs continuous nerve blocks in all patients settings did not inform the specific questions surrounding the use of CISB for shoulder surgery. 76 Consequently, it is not surprising that consensus on the ideal ISB modality for major shoulder surgery has been lacking, and motivation for a change has been minimal. 8 
Limitations
There are some factors that may have biased our findings. First, the relatively small number of trials and their small sample size increases the chance of detecting a treatment effect and/or misestimating its size by mere chance or publication bias. Second, the CISB technique has evolved considerably over time, with modifications to the mode of localisation, volume administered, and block endpoint. The Pere 50 and Tuominen and colleagues 64 studies in particular reflect earlier practices, but sensitivity analysis by removing these studies did not alter the direction or magnitude of the primary outcome results. Third, while all trials examined patients having major shoulder surgeries, a variety of additional shoulder surgeries were also performed, with further variation in anaesthetic practice; possibly contributing to the heterogeneity of results. That said, it is noteworthy that the raw patient data were not available for the majority of trials, which precluded conducting an individual patient meta-analysis to examine major shoulder surgeries in isolation from other procedures. Fourth, the respiratory safety data available were limited to the hospital-monitored setting; we cannot exclude the possibility of dyspnoea or hypoxaemia occurring after discharge. 9 To that end, emerging anatomical evidence suggests that CISB catheter positioning in the 'sub-circum-neural circumneural space' may limit the LA spread to the phrenic nerve, and reduce respiratory complication. 77 Notably, the clinical importance of the observed small changes in respiratory parameters was not clear, as data on oxygen requirement or duration of PACU stay were not available in the trials examining this outcome. Fifth, while our findings regarding the risks and complications of CISB were reassuring, large database studies examining bigger populations can better inform the frequency of such relatively rare outcomes. Sixth, with one exception, 60 none of the trials administered any of the emerging perineural 78, 79 and i.v. 26 adjuvants, or liposomal LA preparations, 80 which have been shown to prolong the analgesic duration of peripheral nerve blocks, and have been proposed as CISB alternatives. 8 However, while these adjuvants may prolong the duration of analgesia produced by a single-injection brachial plexus block by up to 60% 79 or even 80%, 81 the extended duration remains at least 1 day short of that produced by CISB. Furthermore, liposomal LA preparations continue to be restricted to surgical wound local infiltration, and are not approved for perineural use. 82 These limitations of potential contenders underscore the role CISB occupies in managing postoperative pain after shoulder surgery. Finally, none of the trials reviewed examined the influence of pre-operative pain, 83 an important predictor of postoperative pain, on analgesic outcomes. In contrast, our review has several points of strength. Our literature search was exhaustive, included all relevant databases, and was limited to RCTs, yielding an acceptable level of risk of bias across the trials. Additionally, the determinants of ISB efficacy that we pre-identified as potential confounders, namely the LA type, dose, and duration of infusion, successfully explained the heterogeneity of results that we observed, 1 confirming the validity of our findings.
Conclusions
Contemporary evidence suggests that CISB provides superior analgesia compared with SISB after major shoulder surgery without increasing side-effects or complications. There is high level evidence supporting the use of CISB to reduce opioid consumption, improve rest and dynamic pain, and decrease the risk of PONV up to 48 h after major shoulder surgery. Very low level evidence suggests that CISB reduces the respiratory indices compared with SISB, but the clinical importance of such a minor decrease is largely dependent on the baseline respiratory function.
